Tinlarebant for Stargardt disease type 1
The FDA is expected to decide on Tinlarebant for Stargardt disease type 1 by February 12, 2027, under a NDA from Belite Bio.
What is being decided
Belite Bio has a NDA under FDA review for Tinlarebant in Stargardt disease type 1. Would be the first approved treatment for Stargardt disease.
Who this decision matters to
Stargardt disease is the most common inherited macular dystrophy, caused primarily by mutations in the ABCA4 gene that lead to toxic accumulation of lipofuscin (a waste byproduct of the visual cycle) in retinal pigment epithelial cells. This accumulation progressively destroys the macula, the central part of the retina responsible for sharp, detailed vision, resulting in progressive central vision loss that typically begins in childhood or adolescence.
Prevalence: Approximately 1 in 8,000 to 10,000 people; an estimated 30,000 affected individuals in the U.S.. See our full Stargardt Disease page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Stargardt Disease treatment stands today
Stargardt disease has no FDA-approved therapy, but the clinical trial pipeline is one of the most active in inherited retinal disease. Gene therapy approaches using dual-vector AAV systems (the ABCA4 gene is too large for a single AAV vector) are in Phase 1/2 trials. Tinlarebant, an oral visual cycle modulator that reduces lipofuscin accumulation, has shown a 36% reduction in lesion growth in clinical data. Optogenetic therapies and RNA editing approaches are also in early trials. Ask your retinal specialist about your specific ABCA4 mutations (genotype-phenotype correlations can inform prognosis), whether your current disease stage makes you eligible for active gene therapy or pharmacological trials, and whether low-vision rehabilitation services should begin now. Register with the MyRetinaTracker registry through the Foundation Fighting Blindness to be matched with trials as they open.
Meanwhile, 25 Stargardt Disease trials are recruiting
Whatever the FDA decides here, research on Stargardt Disease does not stop. A few currently enrolling studies, US sites first:
Get notified when new stargardt-disease trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Tinlarebant?
The FDA's target decision date (PDUFA date) for Tinlarebant in Stargardt disease type 1 is February 12, 2027, disclosed by Belite Bio. The agency can act before this date and occasionally runs past it.
What is Tinlarebant being reviewed for?
Belite Bio submitted a NDA for Tinlarebant in Stargardt disease type 1. Would be the first approved treatment for Stargardt disease.
What happens after the Tinlarebant decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Belite Bio press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.